Janssen Boosts Metabolism Portfolio with Hanmi Biologic

17.11.2015 - US-based drugs firm Janssen Pharmaceuticals has gained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based treatments for diabetes and...